Clinical trials
Amyloidosis trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alnylam Pharmaceuticals | 5 |
| Ionis Pharmaceuticals, Inc. | 3 |
| Pfizer | 3 |
| Alexion Pharmaceuticals, Inc. | 2 |
| Eidos Therapeutics, a BridgeBio company | 2 |
| Janssen Research & Development, LLC | 2 |
| Akcea Therapeutics | 1 |
| AstraZeneca | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Intellia Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyloidosis | 26 |
| Amyloid Neuropathies, Familial | 7 |
| Cardiomyopathies | 7 |
| Alzheimer Disease | 4 |
| Amyloidosis, Familial | 4 |
| Polyneuropathies | 4 |
| Amyloid Neuropathies | 2 |
| Heart Diseases | 2 |
| Multiple Myeloma | 2 |
| Immunoglobulin Light-chain Amyloidosis | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.